Meta-Analysis: SGLT2 Inhibitors for Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes
16 Nov, 2018 | 01:35h | UTCSGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials – The Lancet (link to abstract – $ for full-text)
Commentary: SGLT2 Inhibitors and CV and Renal Outcomes in Type 2 Diabetes – American College of Cardiology (free)